Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46(5):1453-1463.

Publication Type:

Journal Article

Authors:

Lewis, J.H.; Mortensen, M.E.; Zweig, S.; Fusco, M.J.; Medoff, J.R.; Belder, R.; pravastatin in chronic liver disease study investigators

Source:

Hepatology, Volume 46, Issue 5, p.1453-1463 (2007)

Keywords:

Adult, adverse effects, Aged, Aged,80 and over, Alanine, Alanine Transaminase, Anticholesteremic Agents, blood, Cholesterol, Cholesterol,HDL, Cholesterol,LDL, Chronic Disease, complications, Disease, Double-Blind Method, drug therapy, enzymology, Fatty Liver, Female, hepatitis, Hepatitis C, history, Humans, Hypercholesterolemia, Incidence, Liver, Liver Diseases, Male, Middle Aged, Multicenter Studies, Patients, Pravastatin, Safety, therapeutic use, therapy, Time, treatment, Treatment Outcome, Triglycerides, Washington

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/17668878

Export Citation:

RIS Format

Top